Skip to main content

Table 3 Health state utility weights

From: Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers

Screening and diagnostics   95% CI
 MRI screening* 1.000 -
 Mammography 1.000 -
 Diagnostic workup 0.987 0.761-1.00
Treatment†
 In situ 0.965 0.463-1.00
 Localized 0.860 0.330-1.00
 Regional 0.675 0.315-0.929
 Distant 0.380 0.211-0.564
 Progression (end of life) 0.380 0.211-0.564
 Remission 0.965 0.463-1.00
Dead 0.000 -
Well 1.000 -
  1. Abbreviations: CI Confidence interval.
  2. * Full utility (1.00) assumed for screening states and ‘Well’ state; not varied in probabilistic sensitivity analysis.
  3. † Treatment utilities by stage at diagnosis applied for 18 months, after which ‘Remission’ value applied until progression and death or transition to ‘Well,’ 10-yrs post-diagnosis; utilities for localized, regional, distant disease, and disease progression states were derived from Schleinitz et al.[38], and utility for diagnostic work-up, remission and in situ disease were from Bonomi et al.[39].
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us